+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

GPCR Signaling in Cancer, Vol 145. Advances in Cancer Research

  • ID: 4829384
  • Book
  • February 2020
  • Region: Global
  • 164 Pages
  • Elsevier Science and Technology
1 of 2

GPCR Signaling in Cancer, Volume 145, the latest release in the Advances in Cancer Research series, highlights recent developments in the area of GPCRs and cancer biology. Chapters included in this volume cover several GPCRs and their downstream effectors as case examples to highlight their fundamental understanding and therapeutic potential. Specific chapters address the Role of GRKs and beta-arrestins in cancer, Atypical GPCRs in cancer, the Role of a chemokine receptor (CCR) 5 in cancer, Targeting G protein-coupled receptors for therapeutics in cancer, Emerging GPCR signaling pathways in cancer, and more.

G protein-coupled receptors (GPCRs) constitute a large family of cell surface receptors which are involved in nearly every cellular and physiological event. These receptors can recognize a broad array of ligands and they are targeted by nearly one third of the currently prescribed drugs including anti-cancer therapeutics.

  • Covers the latest concepts in GPCR signaling and their relevancy to cancer biology
  • Presents new indications for anti-cancer therapeutic programs
  • Includes sections on cross-talk and signaling networks of GPCRs and effectors in molecular oncology and therapeutics

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 2
1. HERs Transregulation in Cancer Progression: From Discovery to 2020 and Beyond Rakesh Kumar 2. RTKs in Cancer Biology Paul Fisher 3. Advances in EGFR Biochemistry and Biology Yosef Yarden 4. Mouse Models of RTKs/HERs: Lessons and Implications to Biology and Therapy William Joseph Muller 5. MET Receptor in Oncology: From Biomarker to Therapeutic Target Ravi Salgia 6. RTKs in Pathobiology of Head & Neck Cancer Radhakrishna Pillai 7. HER2 or Nuclear HER/RTK in Cancer Mien-Chie Hung 8. FLT3 in Hematopietic Malignancies: From Pathobiology to Therapeutics Premkumar Reddy 9. Advances in IGF1R Biology and -directed Cancer Therapeutics Douglas Yee 10. Advances in Bcr-Abl in Cancer Therapy and Biology Nandini Verma 11. EphRs in Cancer Development and Progression Renata Pasqualini 12. RTK-directed Clinical Advances: Trials and Treatments Masakazu Toi
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll